BioMarin Pharmaceutical Inc. - Common Stock - Nakit Akışı (NASDAQ:BMRN)

Financials

İşletme faaliyetlerinden elde edilen nakit 85.36 M304.54 M175.9 M159.26 M572.84 M827.99 M 874.25 M Yatırım faaliyetlerinden elde edilen nakit -53.62 M-366.31 M-20.03 M-111.24 M136.49 M-414.24 M 339.52 M Finansman faaliyetlerinden elde edilen nakit 181.12 M-48 K-18.65 M-18.73 M-526.45 M-42.39 M 809.55 M Serbest nakit akışı 85.36 M304.54 M175.9 M159.26 M572.84 M717.02 M 759.12 M

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

BMRN

Financials

BioMarin Pharmaceutical Inc. - Common Stock

Haberler

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

H.C. Wainwright, BioMarin hissesi için Nötr tavsiyesini korudu

BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia

BioMarin hisseleri hipokondroplaziyle ilgili olumlu verilerle yükseldi

BioMarin’in Voxzogo ilacı hipokondroplazi denemesinde başarılı

BMRN Stock Down on Mixed Results From Rare Disease Therapy Study

BioMarin hissesi için hedef fiyat deneme başarısızlığı sonrası düşürüldü

Biomarin hissesi 50,75 dolarda 52 haftalık dibe vurdu

BioMarin hisse hedef fiyatı Freedom Broker tarafından 110 dolara yükseltildi

Goldman Sachs, BioMarin hissesi için rekabet endişeleriyle nötr önerdi

BioMarin 2026 1Ç: Gelir beklentiyi aştı, marj baskısı sürüyor

BioMarin’in ilk çeyrek sonuçları beklentileri aştı, hisse düştü